You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmcinonide
Accession NumberDB00288  (APRD00788)
TypeSmall Molecule
GroupsApproved
DescriptionAmcinonide is a corticosteroid. [Wikipedia]
Structure
Thumb
Synonyms
Amcinonida
Amcinonidum
Triamcinolonacetatcyclopentanonid
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclocortOintment0.1 %TopicalGlaxosmithkline Inc1997-01-20Not applicableCanada
CyclocortLotion0.1 %TopicalGlaxosmithkline Inc1996-09-12Not applicableCanada
CyclocortCream0.1 %TopicalGlaxosmithkline Inc1996-09-12Not applicableCanada
Cyclocort Crm 0.1%Cream.1 %TopicalLederle Cyanamid Canada Inc.1978-12-311997-01-29Canada
Cyclocort Lot 0.1%Lotion.1 %TopicalLederle Cyanamid Canada Inc.1983-12-311997-01-29Canada
Cyclocort Ont 0.1%Ointment.1 %TopicalLederle Cyanamid Canada Inc.1983-12-311997-01-29Canada
Ratio-amcinonideOintment0.1 %TopicalTeva Canada Limited2004-05-05Not applicableCanada
Ratio-amcinonideLotion0.1 %TopicalTeva Canada Limited2004-05-06Not applicableCanada
Ratio-amcinonideCream0.1 %TopicalTeva Canada Limited2003-09-18Not applicableCanada
Taro-amcinonideOintment0.1 %TopicalTaro Pharmaceuticals IncNot applicableNot applicableCanada
Taro-amcinonideCream0.1 %TopicalTaro Pharmaceuticals Inc2003-02-13Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmcinonideCream1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2003-05-15Not applicableUs
AmcinonideOintment1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2003-03-19Not applicableUs
AmcinonideOintment1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2014-04-03Not applicableUs
AmcinonideLotion1 mg/gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2002-11-06Not applicableUs
AmcinonideCream1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2002-05-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MycodermNot Available
PenticortNot Available
VisdermNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII423W026MA9
CAS number51022-69-6
WeightAverage: 502.5717
Monoisotopic: 502.236681679
Chemical FormulaC28H35FO7
InChI KeyILKJAFIWWBXGDU-MOGDOJJUSA-N
InChI
InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1
IUPAC Name
2-[(1'S,2'S,4'R,8'S,9'S,11'S,12'R,13'S)-12'-fluoro-11'-hydroxy-9',13'-dimethyl-16'-oxo-5',7'-dioxaspiro[cyclopentane-1,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-14',17'-dien-8'-yl]-2-oxoethyl acetate
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC1(CCCC1)O2)C(=O)COC(C)=O
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Structured Indications
PharmacodynamicsAmcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture.
Mechanism of actionThe mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Amcinonide has affinity for the glucocorticoid receptor. It has weak affinity for the progesterone receptor, and virtually no affinity for the mineralocorticoid, estrogen, or androgen receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Annexin A1Proteinunknown
agonist
HumanP04083 details
Related Articles
AbsorptionTopical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicityResults from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Amcinonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Amcinonide.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Amcinonide.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Amcinonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Amcinonide.Approved
AldesleukinAmcinonide may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Amcinonide is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Amcinonide can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Amcinonide can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Amcinonide.Approved
AmiodaroneThe serum concentration of Amcinonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BAmcinonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Amcinonide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Amcinonide.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Amcinonide.Approved, Investigational
AprepitantThe serum concentration of Amcinonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Amcinonide can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Amcinonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Amcinonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Amcinonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Amcinonide.Approved, Investigational
BazedoxifeneThe serum concentration of Amcinonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideAmcinonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Amcinonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Amcinonide.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Amcinonide.Investigational
Bismuth SubcitrateThe bioavailability of Amcinonide can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Amcinonide can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Amcinonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Amcinonide.Investigational
BumetanideAmcinonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Amcinonide.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Amcinonide can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Amcinonide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Amcinonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Amcinonide.Experimental
CDX-110The risk or severity of adverse effects can be increased when Amcinonide is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Amcinonide.Approved, Investigational
CeritinibAmcinonide may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Amcinonide.Approved, Vet Approved
ChlorothiazideAmcinonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Amcinonide can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneAmcinonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Amcinonide can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Amcinonide.Approved
CobicistatThe serum concentration of Amcinonide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Amcinonide can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Amcinonide.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Amcinonide is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Amcinonide.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Amcinonide.Investigational
DarunavirThe serum concentration of Amcinonide can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Amcinonide is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Amcinonide.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Amcinonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Amcinonide.Approved, Vet Approved
DienestrolThe serum concentration of Amcinonide can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Amcinonide can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Amcinonide.Approved
DihydrotestosteroneAmcinonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Amcinonide is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Amcinonide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Amcinonide.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Amcinonide.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Amcinonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Amcinonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Amcinonide can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Amcinonide.Approved
EstradiolThe serum concentration of Amcinonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Amcinonide can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Amcinonide can be increased when it is combined with Estrone.Approved
Etacrynic acidAmcinonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Amcinonide.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Amcinonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Amcinonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Amcinonide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Amcinonide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Amcinonide.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Amcinonide.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Amcinonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Amcinonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Amcinonide.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Amcinonide.Vet Approved
FluoxymesteroneAmcinonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Amcinonide.Approved, Investigational
FosaprepitantThe serum concentration of Amcinonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Amcinonide can be decreased when it is combined with Fosphenytoin.Approved
FurosemideAmcinonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Amcinonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Amcinonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Amcinonide is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Amcinonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Amcinonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Amcinonide.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Amcinonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Amcinonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amcinonide.Approved, Investigational
HydrochlorothiazideAmcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAmcinonide may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Amcinonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Amcinonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Amcinonide.Approved
IdelalisibThe serum concentration of Amcinonide can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Amcinonide.Approved
IndapamideAmcinonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Amcinonide can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Amcinonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Amcinonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Amcinonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Amcinonide is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Amcinonide is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Amcinonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Amcinonide.Withdrawn
ItraconazoleThe serum concentration of Amcinonide can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Amcinonide.Experimental
KetoconazoleThe serum concentration of Amcinonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Amcinonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Amcinonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Amcinonide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Amcinonide.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Amcinonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Amcinonide.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Amcinonide.Approved
LumacaftorThe serum concentration of Amcinonide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Amcinonide.Approved, Investigational
MagaldrateThe bioavailability of Amcinonide can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Amcinonide can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Amcinonide can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Amcinonide can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Amcinonide.Approved
Magnesium TrisilicateThe bioavailability of Amcinonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Amcinonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Amcinonide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Amcinonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Amcinonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Amcinonide.Approved
MestranolThe serum concentration of Amcinonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Amcinonide.Withdrawn
MethallenestrilThe serum concentration of Amcinonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideAmcinonide may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneAmcinonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneAmcinonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Amcinonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Amcinonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Amcinonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Amcinonide.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Amcinonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Amcinonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Amcinonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Amcinonide.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Amcinonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Amcinonide.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Amcinonide.Investigational
NefazodoneThe serum concentration of Amcinonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Amcinonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Amcinonide.Approved
NevirapineThe serum concentration of Amcinonide can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Amcinonide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Amcinonide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Amcinonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amcinonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Amcinonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Amcinonide.Vet Approved
OxandroloneAmcinonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Amcinonide.Approved
OxymetholoneAmcinonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Amcinonide.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Amcinonide.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Amcinonide can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Amcinonide can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Amcinonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Amcinonide.Approved, Vet Approved
PhenytoinThe serum concentration of Amcinonide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amcinonide.Approved, Investigational
PiretanideAmcinonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Amcinonide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Amcinonide.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Amcinonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAmcinonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Amcinonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Amcinonide can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Amcinonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Amcinonide.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Amcinonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Amcinonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneAmcinonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Amcinonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide.Experimental, Investigational
RifabutinThe serum concentration of Amcinonide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Amcinonide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Amcinonide can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Amcinonide can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Amcinonide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin.Approved
S EquolThe serum concentration of Amcinonide can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Amcinonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amcinonide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Amcinonide.Approved
SaquinavirThe serum concentration of Amcinonide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Amcinonide can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Amcinonide.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Amcinonide.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Amcinonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Amcinonide.Investigational
St. John's WortThe serum concentration of Amcinonide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololAmcinonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Amcinonide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Amcinonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Amcinonide.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Amcinonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Amcinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Amcinonide.Approved
TelithromycinThe serum concentration of Amcinonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Amcinonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Amcinonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Amcinonide.Approved
TestosteroneAmcinonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Amcinonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Amcinonide.Approved
TiboloneThe serum concentration of Amcinonide can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Amcinonide.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Amcinonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Amcinonide.Approved
TorasemideAmcinonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Amcinonide.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Amcinonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideAmcinonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Amcinonide.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Amcinonide.Investigational, Withdrawn
VoriconazoleThe serum concentration of Amcinonide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAmcinonide may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Amcinonide.Approved
ZeranolThe serum concentration of Amcinonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Amcinonide.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Amcinonide.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Schultz, W., Sieger, G.M. and Krieger, C.: British Patent 1,442,925; July 14,1976; assigned to
American Cyanamid Company.

General ReferencesNot Available
External Links
ATC CodesD07AC11
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (143 KB)
MSDSDownload (48.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9643
Blood Brain Barrier+0.9897
Caco-2 permeable-0.5844
P-glycoprotein substrateSubstrate0.7713
P-glycoprotein inhibitor IInhibitor0.7198
P-glycoprotein inhibitor IIInhibitor0.5596
Renal organic cation transporterNon-inhibitor0.7608
CYP450 2C9 substrateNon-substrate0.8615
CYP450 2D6 substrateNon-substrate0.9016
CYP450 3A4 substrateSubstrate0.7307
CYP450 1A2 substrateNon-inhibitor0.8688
CYP450 2C9 inhibitorNon-inhibitor0.8732
CYP450 2D6 inhibitorNon-inhibitor0.8982
CYP450 2C19 inhibitorNon-inhibitor0.9188
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8999
Ames testNon AMES toxic0.8886
CarcinogenicityNon-carcinogens0.941
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4315 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9488
hERG inhibition (predictor II)Non-inhibitor0.5298
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Altana inc
  • Taro pharmaceutical industries ltd
  • Astellas pharma us inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical1 mg/g
LotionTopical1 mg/g
OintmentTopical1 mg/g
CreamTopical0.1 %
LotionTopical0.1 %
OintmentTopical0.1 %
CreamTopical.1 %
LotionTopical.1 %
OintmentTopical.1 %
Prices
Unit descriptionCostUnit
Amcinonide 0.1% Cream 60 gm Tube84.29USD tube
Amcinonide 0.1% Ointment 60 gm Tube84.29USD tube
Amcinonide 0.1% Cream 30 gm Tube28.71USD tube
Amcinonide 0.1% Cream 15 gm Tube20.99USD tube
Amcinonide 0.1% cream1.68USD g
Cyclocort 0.1 % Cream0.62USD g
Cyclocort 0.1 % Ointment0.62USD g
Cyclocort 0.1 % Lotion0.52USD g
Ratio-Amcinonide 0.1 % Ointment0.33USD g
Ratio-Amcinonide 0.1 % Cream0.29USD g
Taro-Amcinonide 0.1 % Cream0.29USD g
Ratio-Amcinonide 0.1 % Lotion0.27USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00774 mg/mLALOGPS
logP3.16ALOGPS
logP3.2ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.63ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity127.88 m3·mol-1ChemAxon
Polarizability52.23 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Acetate salt
  • Cyclic alcohol
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  4. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  5. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  6. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  7. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Structural molecule activity
Specific Function:
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions ...
Gene Name:
ANXA1
Uniprot ID:
P04083
Molecular Weight:
38713.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Serres M, Comera C, Schmitt D: Annexin 1 regulation in human epidermal cells. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):701-6. [PubMed:7981624 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23